Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Broker tips: Greggs, Haleon

(Sharecast News) - Numis initiated coverage of Greggs on Wednesday with a 'hold' rating and 2,560p price target as it said growth was "baked in". Greggs is "the undisputed UK food-to-go specialist", it said, with a share of around 8% of a "highly fragmented" market.

Numis said the company's track record is impressive, reporting 10-year CAGR store growth of 3.4%, revenue of 7.5% and pre-tax profit of 11.3%.

It noted that in 2021, management set out to double revenue from £1.2bn to £2.4bn by 2026 and has already achieved half of this.

"However, over the next three years an increasing amount of this growth will originate from franchisees, delivery and loyalty, all dilutive to gross margin and in most instances to EBIT margin too meaning we forecast profit before tax CAGR of circa 10%," it said.

"The shares are trading at 20x FY24E price-to-earnings rate, in line with five-year average and therefore we initiate with a hold."

The broker said it prefers Domino's, which has a clearer growth trajectory, is less capital intensive and trades at an 8% discount to Greggs.

JPMorgan placed consumer health company Haleon on 'negative catalyst' watch ahead of its annual report next month, saying volume and earnings risks will weigh on the stock's rating.

The bank cut its target price for the Sensodyne, Panadol and Advil manufacturer from 295p to 290p and reiterated an 'underperform' rating.

"Having delivered strong volumes vs staples peers over the past two years, we expect top line to disappoint as the tailwinds that boosted its OTC divisions abate. Volumes should remain pressured vs sequential improvement for peers," JPMorgan said.

The bank highlighted the unravelling of Covid-led tailwinds like higher flu incidence and China's Covid wave, as well as a muted performance in the rest of the business.

JPMorgan expects 2024 like-for-like sales to grow by just 3.7%, below the company's guidance of 4-6%, and forecasts a "pedestrian margin rise" given headwinds including slowing volumes, FX movements, and dilution from the disposal of Lamisil last year.

Share this article

Related Sharecast Articles

London close: Footsie hits another record, but BoE comments limit gains
(Sharecast News) - A weak performance from the heavyweight mining sector wasn't enough to stop the FTSE 100 from reaching a new record high on Tuesday, as London's blue-chip index rose for the fifth straight day.
Broker tips: HSBC, Reckitt Benckisser, Watches of Switzerland
(Sharecast News) - Citi said on Tuesday that it remains 'overweight' UK banks, with HSBC one of its top picks.
Director dealings: Porvair CFO raises stake
(Sharecast News) - Porvair revealed on Tuesday that chief financial officer James Mill had acquired 4,250 ordinary shares in the London-listed filtration and environmental technology group.
Europe close: Stocks rise as investors digest PMI data
(Sharecast News) - European markets closed above the waterline on Tuesday, propelled by positive survey data from the eurozone that bolstered investor sentiment.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.